<DOC>
	<DOCNO>NCT02847091</DOCNO>
	<brief_summary>The objective study assess reduction insulin dose baseline Week 24 keep blood glucose level control ( maintain HbA1c value ) ipragliflozin administer daily 24 week patient type 2 diabetes mellitus receive insulin therapy .</brief_summary>
	<brief_title>Study Ipragliflozin Patients With Type 2 Diabetes Mellitus Receiving Insulin Therapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>The subject receive insulin therapy treatment diabetes mellitus . The subject type 2 diabetes mellitus receive insulin monotherapy insulin therapy combination one two oral hypoglycemic agent . The subject modify diet exercise therapy dosage regimen oral hypoglycemic agent , switch another pharmacotherapy 12 week Visit 1 . The subject HbA1c value 6.5 % &lt; 8.0 % . The subject body mass index ( BMI ) &gt; 23.0 kg/m2 . If subject female , must satisfy follow criterion . The subject childbearing potential satisfies follow criterion . The subject postmenopausal ( absence menses least 1 year ) . The subject surgically sterile . The subject childbearing potential satisfies follow criterion : The subject agree get pregnant 28 day last dose study drug . The subject negative pregnancy test . The subject agree use two establish contraceptive method list 28 day last dose study drug heterosexual intercourse . If subject female , must agree breastfeed 28 day last dose study drug . If subject female , must agree donate egg period assessment 28 day last dose study drug . In case male subject 's spouse partner childbearing potential , subject must agree use two establish contraceptive method 28 day last dose study drug . If subject male , must agree donate sperm 28 day last dose study drug . The subject type 1 diabetes mellitus . The subject symptom dysuria , anuria , oliguria urinary retention . The subject proliferative retinopathy . The subject diabetic ketoacidosis . The subject history complication medically significant renal disease renovascular occlusive disease , nephrectomy and/or renal transplant . The subject history recurrent urinary tract infection . The subject symptomatic urinary tract infection symptomatic genital infection . The subject chronic disease ( ) require continuous use corticosteroid , immunosuppressant , etc . The subject history cerebral vascular attack , unstable angina , myocardial infarction , vascular intervention , serious heart disease within 1 year ( 52 week ) sign informed consent . The subject complication surgical history serious gastrointestinal disorder . The subject severe hepatic dysfunction . The subject uncontrolled blood pressure . The subject unstable psychiatric disorder . The subject severe infection serious trauma , perioperative . The subject drug addiction alcohol abuse . The subject history malignant tumor . The subject history allergy ipragliflozin and/or similar drug ( drug possess SGLT2 inhibitory action ) . The subject use SGLT2 inhibitor , GLP1 receptor agonist , sulfonylurea ( SU ) , glinide agent , insulin product longacting insulin within 12 week sign informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Ipragliflozin</keyword>
	<keyword>SGLT2 inhibitor</keyword>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>ASP1941</keyword>
</DOC>